Trajenta

Trajenta

linagliptin

Manufacturer:

Boehringer Ingelheim
Concise Prescribing Info
Contents
Linagliptin
Indications/Uses
Adult patients w/ type 2 DM (T2DM) to improve glycaemic control in conjunction w/ diet & exercise, as add on to metformin, sulphonylureas, or metformin plus sulphonylureas or metformin (≥1,500 mg/day) plus empagliflozin.
Dosage/Direction for Use
Administration
May be taken with or without food.
Contraindications
Special Precautions
Not for type 1 DM or for treatment of diabetic ketoacidosis. Discontinue if pancreatitis is suspected. Hypoglycaemia. Pregnancy & lactation. Childn <18 yr.
Adverse Reactions
Hypoglycaemia. Angioedema, urticaria, rash & mouth ulceration. Increased lipase.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BH05 - linagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.
Presentation/Packing
Form
Trajenta FC tab 5 mg
Packing/Price
3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in